GHRH (1-29)
Also known as: Sermorelin, GH-RH (1-29), hGRF (1-29), hGHRH (1-29), [Nle27]GHRH (1-29)-NH2, GHRH (1-29)-NH2, Growth Hormone-Releasing Hormone (1-29)
Hypothalamic neuropeptide / GH secretagogue — synthetic analog of endogenous growth hormone-releasing hormone
What it is
GHRH (1-29) is used in clinical testing to assess how well the pituitary gland responds to growth hormone signals, and is studied for treating GH deficiency in children. It works by directly stimulating the pituitary to release its own growth hormone. Not FDA-approved in this form; studied in diagnostic and pediatric applications.
The scientific side
GHRH (1-29) is a 29-amino-acid fragment of endogenous hypothalamic growth hormone-releasing hormone that stimulates GH secretion from the anterior pituitary gland. It acts through the pituitary-type GHRH receptor (pGHRH-R) and its splice variants, particularly SV1, which are expressed on pituitary somatotrophs and — as an autocrine/paracrine system — on a variety of extrapituitary and tumor cells (PMID 18506184, PMID 24186980 [not present — see PMID 12186980]). Receptor binding elevates cAMP and activates downstream signaling cascades including ERK1/2, JAK2/STAT3, MAPK, and PKA pathways (PMID 19897610, PMID 17448980 [not present — see PMID 20232355]). In cancer-focused research, synthetic GHRH antagonists (not the agonist peptide itself) have been developed to block this receptor, suppressing tumor growth and inflammation (PMID 41075421, PMID 32289177). As an agonist, GHRH (1-29) stimulates pulsatile GH release; pulsatile GH release can be reconstituted in vivo by combining continuous GHRH with intermittent somatostatin withdrawal. The GH-releasing effect requires functional somatotrophs: patients with direct pituitary damage show attenuated responses even to supramaximal doses. The D-Ala2 substitution reduces metabolic clearance and extends half-life relative to the native peptide. Note: this is the synthetic 29-residue research fragment; for the full-length endogenous GHRH (1-44), see /peptides/ghrh.
Class: Hypothalamic neuropeptide / GH secretagogue — synthetic analog of endogenous growth hormone-releasing hormone
Administration & storage
- Administration
- Intravenous bolus (PMID: 10754477PMID: 7921207PMID: 9579235)Intravenous continuous infusion (PMID: 10594518PMID: 8810733PMID: 7962295)Subcutaneous injection — once or twice dailypatient self-administered (PMID: 8772599PMID: 9141536PMID: 9231053PMID: 7955460PMID: 1379256PMID: 9005976PMID: 9360512)Subcutaneous continuous infusion (PMID: 8329829PMID: 10594518)Intranasal insufflation — low bioavailability (~3–5%) reported (PMID: 8329825PMID: 8329828)
- Storage
- No abstract in the reviewed set explicitly describes storage conditions for GHRH (1-29) preparations.
- Cautions
- GHRH antibodies developed in nearly all children receiving subcutaneous GHRH(1-29)-NH2 for 6 months, though antibody titers did not correlate with height gain and largely disappeared by 9 months after stopping treatment.,Intranasal GHRH(1-29)-NH2 caused local reactions (sneezing, rhinorrhoea, mild mucosal burning) in most pediatric patients; two children discontinued treatment early; decreasing absorption and antibody development occurred over 6 months.,Mild injection-site irritation was reported in 3 patients receiving subcutaneous GHRH(1-29)-NH2 infusion over 6 months.,Transient hyperlipidemia was observed during 16-week nightly GHRH analog administration in age-advanced adults and resolved by end of study.,Fasting blood glucose and insulin levels increased during 12-month twice-daily GHRH(1-29)NH2 therapy in children with idiopathic short stature; monitoring of glucose metabolism is warranted.,Sterile technique should be used for all injectable preparations to prevent contamination.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- GH stimulation testing / diagnostic use in GH deficiency Human observational
- Bolus GHRH(1-29)NH2 at doses of 0.05, 0.15, and 1.0 µg/kg i.v. elicited significantly lower peak GH and AUC in long-term survivors of childhood brain tumors compared to controls, demonstrating attenuated pituitary responsiveness after cranial irradiation. PMID 10754477 Achermann et al. (2000) Eur J Endocrinol
- 3-hour escalating-dose GHRH(1-29) infusion (0.2–0.6 µg/kg/h plus 2 µg/kg i.v. bolus) discriminated pituitary stalk abnormalities from other causes of GHD; impaired GH response was strikingly indicative of pituitary stalk pathology. PMID 8810733 Maghnie et al. (1996) Eur J Endocrinol
- GHRH (1-29)NH2 priming (5 µg/kg s.c. for 6 days) separated hypothalamic from pituitary GH deficiency in short-statured children; responders showed GH rise from 6.0 to 18.0 ng/ml after priming (p<0.001). PMID 7735368 Bueno et al. (1994) J Pediatr Endocrinol
- Dose-response study: 10 and 100 µg i.v. bolus GHRH(1-29)NH2 produced significant peak GH responses in adult male volunteers; 1 µg did not. Higher doses delayed time to peak and prolonged GH elevation. PMID 7921207 Spoudeas et al. (1994) Eur J Endocrinol
- Treatment of radiation-induced GH deficiency in children Human observational
- GHRH(1-29)-NH2 15 µg/kg twice daily s.c. for 1 year increased height velocity from 3.3 to 6.0 cm/year (p=0.004) in 9 cranially irradiated children with GHD. No adverse biochemical changes were noted. PMID 9231053 Ogilvy-Stuart et al. (1997) Clin Endocrinol
- Continuous GHRH(1-29)NH2 infusion (60 ng/kg/min s.c., 24 h) amplified peak GH in irradiated survivors but concentrations remained far below controls, suggesting combined hypothalamic/pituitary deficits. PMID 10594518 Achermann et al. (1999) Clin Endocrinol
- Treatment of GH deficiency / idiopathic short stature in children Human RCT
- 30 µg/kg/day GHRH(1-29) s.c. once daily at bedtime for 1 year increased mean height velocity from 4.1 to 8.0 cm/year at 6 months and 7.2 cm/year at 12 months in 86 prepubertal GHD children. Well tolerated with no adverse biochemical changes. PMID 8772599 Thorner et al. (1996) J Clin Endocrinol Metab
- GHRH(1-29)NH2 20 µg/kg twice daily s.c. for 12 months increased height velocity from 4.8 to 7.2 cm/year (p=0.001) in 18 short prepubertal children with idiopathic short stature. Catch-down growth occurred after stopping. PMID 7955460 Kirk et al. (1994) Clin Endocrinol
- Once-nightly s.c. injections of GHRH 1-29 (30 µg/kg) for 6 months produced similar increases in growth rate in children with idiopathic short stature and GH neurosecretory dysfunction. Growth rates were not significantly different from pre-therapy rates 6 months after discontinuation. PMID 10905389 Schwartz et al. (2000) J Pediatr Endocrinol Metab
- RCT in 43 prepubertal GHD children: GHRH(1-29)-NH2 30 µg/kg/day (3 doses) vs 60 µg/kg/day vs GH 0.1 IU/kg/day for 6 months. Height velocity was comparable in the HD and GH groups; GH group had greater height SDS for bone age. PMID 8329826 Neyzi et al. (1993) Acta Paediatr Suppl
- RCT in 60 hypothalamic GHD children: GHRH(1-29)-NH2 30 or 60 µg/kg/day vs GH 0.1 IU/kg/day for 6 months. Growth was significantly better in the GH group. GHRH antibodies developed in nearly all GHRH-treated patients but did not correlate with height gain. Mild injection-site irritation in 3 patients. PMID 8329830 Chen et al. (1993) Acta Paediatr Suppl
- Restoration of GH/IGF-I axis in aging men and women Human RCT
- Single-blind RCT: [Nle27]GHRH(1-29)-NH2 10 µg/kg s.c. nightly for 16 weeks in 19 age-advanced men and women significantly increased nocturnal GH, IGF-I, and IGFBP-3. Increased lean body mass, insulin sensitivity, general well-being, and libido in men. Transient hyperlipidemia resolved by study end. PMID 9141536 Khorram et al. (1997) J Clin Endocrinol Metab
- High-dose GHRH-(1-29) s.c. twice daily (1 mg) for 14 days reversed age-related decreases in 24-h GH and IGF-I in old men to levels not significantly different from young men. No adverse effects on glucose, blood pressure, or chemistry. PMID 1379256 Corpas et al. (1992) J Clin Endocrinol Metab
- Eleven elderly men (64–76 yr) received nightly s.c. self-injections of 2 mg GHRH for 6 weeks; increased nocturnal GH parameters and improved 2 of 6 muscle strength measures. IGF-I levels did not significantly change. No significant adverse effects. PMID 9005976 Vittone et al. (1997) Metabolism
- Immune function enhancement in aging Human RCT
- Single-blind RCT: [Nle27]GHRH(1-29)-NH2 10 µg/kg s.c. nightly for 16 weeks in 19 elderly men and women produced significant increases in B cells, T cell receptor expression, IL-2 production, NK-cell-related markers, and immunoglobulin levels. No sex differences in immune response; no adverse effects. PMID 9360512 Khorram et al. (1997) J Clin Endocrinol Metab
- GH pulse generation research (physiological studies) Human RCT
- Continuous GHRH(1-29)NH2 infusion (60 ng/kg/min s.c.) combined with intermittent somatostatin withdrawal produced regular GH pulses in normal volunteers, providing evidence for GHRH's role in GH synthesis and replenishment. PMID 10594518 Achermann et al. (1999) Clin Endocrinol
- GHRH antagonist (400 µg/kg i.v.) blocked 95% of GH response to exogenous GHRH bolus and eliminated most of the GH response to GHRP-6, demonstrating that endogenous GHRH is necessary for most of the GH response to GHRP-6. PMID 9543138 Pandya et al. (1998) J Clin Endocrinol Metab
- Autocrine/paracrine growth factor in cancer cells (in vitro / preclinical) Animal studies only
- GHRH(1-29)NH2 stimulated proliferation of H-69 and H-510A small cell lung carcinoma lines in vitro. GHRH antagonist JV-1-36 inhibited proliferation and reduced tumor volume in nude mice bearing H-69 xenografts. PMID 10611309 Kiaris et al. (1999) Proc Natl Acad Sci USA
- Exogenous GHRH(1-29)NH2 re-established proliferation of breast, prostate, and NSCLC cancer cell lines after GHRH gene silencing by siRNA, confirming GHRH as a tumoral autocrine growth factor. PMID 18506184 Barabutis & Schally (2008) Br J Cancer
- GHRH(1-29)NH2 at 10^-8 to 10^-6 M increased proliferation and VEGF and chromogranin A secretion in NCI-H727 bronchial neuroendocrine tumor cells in vitro. PMID 19747727 Stepień et al. (2009) Neuropeptides
- GHRH receptor antagonists — anti-tumor and anti-inflammatory applications (preclinical and in vitro) Mixed
- GHRH antagonist JV-1-36 induced autophagy (elevated ATG-5, ATG-3, ATG-7, ATG-16L1) in MDA-MB-468 and A549 cancer cells expressing GHRH receptors; no effect in MCF-7 cells lacking GHRH receptors. PMID 41075421 Sigdel et al. (2025) Growth Horm IGF Res
- GHRH-R antagonist MIA-690 combined with EGFR inhibitor gefitinib showed synergistic inhibition of PC-3 CRPC cell viability, adhesion, and metalloprotease activity in vitro and in nude mouse xenografts. PMID 39456984 Muñoz-Moreno et al. (2024) Int J Mol Sci
- GHRH antagonist MIA-602 inhibited SARS-CoV-2 spike protein + LPS-induced inflammation in macrophages and PBMCs, suppressing TNF-α, IL-1β, NF-κB, STAT3, and oxidative stress markers. PMID 37649486 Granato et al. (2023) Front Immunol
Protocol
100 mcg subcutaneous injection, once daily, pre-sleep. Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous bolus | 0.05, 0.15, or 1.0 µg/kg i.v. bolus | Single administration | human | Research PMID 10754477 |
| Intravenous infusion and bolus | Escalating infusion: 0.2 µg/kg/h (1 h), 0.4 µg/kg/h (1 h), 0.6 µg/kg/h (1 h), then 2 µg/kg i.v. bolus | 3-hour infusion plus bolus | human | Research PMID 8810733 |
| Subcutaneous (priming); intravenous bolus (test) | Priming: 5 µg/kg s.c. once daily for 6 days; test: 1 µg/kg i.v. bolus on day 7 | 6 days priming plus 1-day test | human | Research PMID 7735368 |
| Intravenous bolus | 1, 10, or 100 µg i.v. bolus | Single administration | human | Research PMID 7921207 |
| Subcutaneous injection | 15 µg/kg twice daily | 12 months | human | Research PMID 9231053 |
| Subcutaneous infusion | 60 ng/kg/min continuous infusion (24 h) | 24 hours | human | Research PMID 10594518 |
| Subcutaneous injection | 30 µg/kg once daily at bedtime | 12 months | human | Research PMID 8772599 |
| Subcutaneous injection | 20 µg/kg twice daily | 12 months | human | Research PMID 7955460 |
| Subcutaneous injection | 30 µg/kg once nightly | 6 months | human | Research PMID 10905389 |
| Subcutaneous injection | 30 µg/kg/day (3 divided doses) or 60 µg/kg/day (3 divided doses) | 6 months | human | Research PMID 8329826 |
| Subcutaneous injection (continuous infusion in some patients) | 30 or 60 µg/kg/day | 6 months | human | Research PMID 8329830 |
| Subcutaneous injection (self-administered) | 10 µg/kg nightly | 16 weeks | human | Research PMID 9141536 |
| Subcutaneous injection | 0.5 mg or 1 mg twice daily | 14 days | human | Research PMID 1379256 |
| Subcutaneous injection (self-administered) | 2 mg nightly | 6 weeks | human | Research PMID 9005976 |
| Subcutaneous injection (self-administered) | 10 µg/kg nightly | 16 weeks | human | Research PMID 9360512 |
| Intravenous bolus | 400 µg/kg (GHRH antagonist, for GHRH blockade study) | Single administration | human | Research PMID 9543138 |
| Intranasal; intravenous | Intranasal: 50 µg/kg three times daily; intravenous: 0.25–2 µg/kg | Single administration (PK study) | human | Research PMID 8329825 |
| Intranasal | 50 µg/kg three times daily intranasally | 6 months | human | Research PMID 8329828 |
| Subcutaneous continuous infusion | Continuous subcutaneous infusion, dose not explicitly stated in abstract | 6 months | human | Research PMID 8329829 |
| Intravenous infusion | 25 ng/kg/min constant i.v. infusion (GHRH-(1-29)-NH2 and D-Ala2-GHRH-(1-29)-NH2) | 90-minute infusion | human | Research PMID 7962295 |
| Intravenous bolus | 50 µg i.v. bolus | Single administration | human | Research PMID 11816525 |
| Intravenous bolus | 1.0 µg/kg i.v. bolus (in combination studies with CRH, ACTH, hydrocortisone) | Single administration | human | Research PMID 9579235 |
| In vitro cell culture | 10^-8 to 10^-6 M | Not specified in abstract | in_vitro | Research PMID 19747727 |
| Subcutaneous (antagonist; in vivo) | Not explicitly stated for in vitro; antagonist JV-1-36 administered s.c. in nude mice | 31 days (in vivo) | animal | Research PMID 10611309 |
| subcutaneous injection | 100 mcg | once daily, pre-sleep · 8-12 weeks | biohackers and athletes seeking GH optimization / anti-aging | [Community] |
| subcutaneous injection | 200 mcg | once daily, pre-sleep · 8-12 weeks | biohackers and athletes seeking more aggressive GH optimization | [Community] |
| subcutaneous injection | 100 mcg | twice daily (morning and pre-sleep) · 8-16 weeks | experienced biohackers and performance athletes | [Community] |
| subcutaneous injection | 100 mcg | three times daily (morning, post-workout, pre-sleep) · 8-12 weeks | advanced bodybuilders and performance athletes | [Community] |
| subcutaneous injection | 100 mcg | once daily, pre-sleep · 12-16 weeks | adults 40+ pursuing longevity and hormone restoration | [Community] |
| subcutaneous injection | 200 mcg | twice daily (morning and pre-sleep) · 8-12 weeks | advanced biohackers and bodybuilders | [Community] |
| subcutaneous injection | 100 mcg | once daily, pre-sleep · ongoing / indefinite (with periodic breaks) | longevity-focused biohackers using peptides as part of a long-term stack | [Community] |
| subcutaneous injection | 100 mcg | once daily, pre-sleep · 4-6 weeks | beginners or those trialing peptides for the first time | [Community] |
All studies (34)
- PMID 1379256 Human RCT
Restoration of GH/IGF-I axis in aging men and women - PMID 7955460 Human RCT
Treatment of GH deficiency / idiopathic short stature in children - PMID 8329826 Human RCT
Treatment of GH deficiency / idiopathic short stature in children - PMID 8329830 Human RCT
Treatment of GH deficiency / idiopathic short stature in children - PMID 8772599 Human RCT
Treatment of GH deficiency / idiopathic short stature in children - PMID 9005976 Human RCT
Restoration of GH/IGF-I axis in aging men and women - PMID 9141536 Human RCT
Restoration of GH/IGF-I axis in aging men and women - PMID 9360512 Human RCT
Immune function enhancement in aging - PMID 9543138 Human RCT
GH pulse generation research (physiological studies) - PMID 10905389 Human RCT
Treatment of GH deficiency / idiopathic short stature in children - PMID 7735368 Human observational
GH stimulation testing / diagnostic use in GH deficiency - PMID 7921207 Human observational
GH stimulation testing / diagnostic use in GH deficiency - PMID 8810733 Human observational
GH stimulation testing / diagnostic use in GH deficiency - PMID 9231053 Human observational
Treatment of radiation-induced GH deficiency in children - PMID 10594518 Human observational
Treatment of radiation-induced GH deficiency in children - PMID 10754477 Human observational
GH stimulation testing / diagnostic use in GH deficiency - PMID 37649486 Mixed
GHRH receptor antagonists — anti-tumor and anti-inflammatory applications (preclinical and in vitro) - PMID 39456984 Mixed
GHRH receptor antagonists — anti-tumor and anti-inflammatory applications (preclinical and in vitro) - PMID 41075421 Mixed
GHRH receptor antagonists — anti-tumor and anti-inflammatory applications (preclinical and in vitro) - PMID 7962295
25 ng/kg/min constant i.v. infusion (GHRH-(1-29)-NH2 and D-Ala2-GHRH-(1-29)-NH2) Intravenous infusion (human) - PMID 8329825
Intranasal: 50 µg/kg three times daily; intravenous: 0.25–2 µg/kg Intranasal; intravenous (human) - PMID 8329828
50 µg/kg three times daily intranasally Intranasal (human) - PMID 8329829
Continuous subcutaneous infusion, dose not explicitly stated in abstract Subcutaneous continuous infusion (human) - PMID 9579235
1.0 µg/kg i.v. bolus (in combination studies with CRH, ACTH, hydrocortisone) Intravenous bolus (human) - PMID 10611309 Animal studies only
Autocrine/paracrine growth factor in cancer cells (in vitro / preclinical) - PMID 11816525
50 µg i.v. bolus Intravenous bolus (human) - PMID 12186980
- PMID 17448980
- PMID 18506184 Animal studies only
Autocrine/paracrine growth factor in cancer cells (in vitro / preclinical) - PMID 19747727 Animal studies only
Autocrine/paracrine growth factor in cancer cells (in vitro / preclinical) - PMID 19897610
- PMID 20232355
- PMID 24186980
- PMID 32289177